World Health Organ Tech Rep Ser. 2012(973):1-26.
This report presents the recommendations of a WHO Expert Committee responsible for reviewing information on psychoactive substances to assess the need for their international control. The report contains a summary of the Committee's evaluations of gamma-hydroxybutyric acid (GHB) and ketamine. GHB was recommended to be rescheduled from Schedule IV to Schedule II of the Convention on Psychotropic Substances. The report also discusses the nine substances that were pre-reviewed: dextromethorphan, tapentadol, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl) piperazine (TFMPP), 1-(3-chlorophenyl)piperazine (mCPP), 1-(4-methoxyphenyl)piperazine (MeOPP), 1-(3,4-methylenedioxybenzyl)piperazine (MDBP), gamma-butyrolactone (GBL), and 1,4-butanediol (1,4-BD). Of these, tapentadol, BZP, GBL and 1,4-BD were recommended for critical review. Issues identified for consideration at future Expert Committee meetings are also listed. Furthermore, the report discusses the use of terms, the use of pharmacovigilance data for the assessment of abuse and dependence potential, balancing medical availability and prevention of abuse of medicines manufactured from controlled substances, and improving the process for substance evaluation.
本报告介绍了世界卫生组织一个专家委员会的建议，该委员会负责审查有关精神活性物质的信息，以评估对其进行国际管制的必要性。报告包含了委员会对γ-羟基丁酸（GHB）和氯胺酮评估的摘要。建议将GHB从《精神药物公约》附表四重新列入附表二。报告还讨论了预先审查的九种物质：右美沙芬、曲马多、N-苄基哌嗪（BZP）、1-（3-三氟甲基苯基）哌嗪（TFMPP）、1-（3-氯苯基）哌嗪（mCPP）、1-（4-甲氧基苯基）哌嗪（MeOPP）、1-（3,4-亚甲二氧基苄基）哌嗪（MDBP）、γ-丁内酯（GBL）和1,4-丁二醇（1,4-BD）。其中，曲马多、BZP、GBL和1,4-BD被建议进行严格审查。还列出了在未来专家委员会会议上确定需审议的问题。此外，报告讨论了术语的使用、利用药物警戒数据评估滥用和依赖潜力、平衡医疗可及性与防止对由管制物质制成的药品的滥用，以及改进物质评估程序。
